p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: A cohort study

International Journal of Clinical Oncology

Volumn 11, Issue 6, 2006, Pages 426-433

  Kai, Kazuharu ^a,b   Nishimura, Reiki ^b   Arima, Nobuyuki ^b   Miyayama, Haruhiko ^b   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

p53 expression status; Response to first line endocrine therapy; Time to endocrine therapy failure

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FADROZOLE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MOLECULAR MARKER; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33845759420     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0601-6     Document Type: Article

References (22)

1. DR Ciocca R Elledge 2000 Molecular markers for predicting response to tamoxifen in breast cancer patients Endocrine 13 1 10
2. CG Kardinal 2002 Hormonal and endocrine therapy of breast cancer WL Donegan JS Spratt Cancer of the breast, fifth edn Elsevier Science St. Louis 693 737
3. AE Ring PA Ellis 2002 Predictors of response to systemic therapy in breast cancer Forum Genova 12 19 32
4. CK Osborne J Shou S Massarweh 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865 870
5. G Arpino SJ Green DC Allred 2004 HER2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study Clin Cancer Res 10 5670 5676
6. MJ Ellis A Coop B Singh 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808 3816
7. JM Dixon J Jackson M Hills 2004 Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status Eur J Cancer 40 2742 2747
8. EM Berns JA Foekens R Vossen 2000 Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60 2155 2162
9. PL Fitzgibbons DL Page D Weaver 2000 Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966 978
10. GN Hortobagyi 1998 Treatment of breast cancer N Engl J Med 339 974 984
11. JL Hayward PP Carbone JC Heuson 1977 Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 39 1289 1294
12. H de Haes M Olschewski M Kaufmann 2003 Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group J Clin Oncol 21 4510 4516
13. M Piccart LM Parker KI Pritchard 2003 Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann Oncol 14 1017 1025
14. K Shimozuma H Sonoo K Ichihara 1995 Analysis of the factors influencing the quality of life of patients with advanced or recurrent breast cancer Surg Today 25 874 882
15. J Kurebayashi H Sonoo H Inaji 2000 Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies Oncology 59 31 37
16. SG Archer A Eliopoulos D Spandidos 1995 Expression of ras parn21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy Br J Cancer 72 1259 1266
17. RM Elledge S Green L Howes 1997 bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study J Clin Oncol 15 1916 1922
18. J Bergh T Norberg S Sjogren 1995 Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nat Med 1 1029 1034
19. R Silvestrini E Benini S Veneroni 1996 p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients J Clin Oncol 14 1604 1610
20. EM Berns JG Klijn MP Look 2003 Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer Clin Cancer Res 9 1253 1258
21. EM Berns JG Klijn WL van Putten 1998 p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer J Clin Oncol 16 121 127
22. GM Horne JJ Anderson DG Tiniakos 1996 p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry Br J Cancer 73 29 35